ArticleBMC nephrology2025
Epidemiology, clinical features and outcomes of patients with kidney biopsy proven IgA vasculitis in Auckland and Northland, Aotearoa, New Zealand presenting between 2003-2020.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsImmunoglobulin A vasculitis is a small vessel vasculitis. Here we describe the epidemiology, clinical features, treatment and outcomes in patients, over the age of 16 years, with kidney biopsy proven cases seen in two regions of Aotearoa, New Zealand over an 18-year period.
methodsPotential cases were identified, in patients over the age of 16 years, who underwent kidney biopsy between 2003 and 2020. A retrospective review of all potential cases was performed.
resultsThirty-four patients were identified, 10 females and 24 males, of whom 15 were European, 5 Māori, 7 Pacific Peoples, and 7 Asians. The incidence was 1.16 per 1,000,000 patient-years (95% CI: 0.82-1.61), there was an excess in males (RR = 2.42 95% CI 1.16-5.06, p = 0.016) with no excess by ethnicity. Mean age at presentation was 42.8 years (range 16.4-70.5). Mean creatinine at presentation was 118µmol/L (range 51-410). Twenty-six patents received corticosteroids, with two patients also receiving cyclophosphamide and five patients receiving azathioprine. Six patients (17.6%) needed long-term kidney replacement therapy, 12 were left with significant chronic kidney disease (35.3%) and 4 died (11.8%) at the end of study follow up. Elevated serum creatinine at presentation was predictive of need for kidney replacement therapy. Age was predictive of mortality.
conclusionsImmunoglobulin A vasculitis is not overrepresented among indigenous people in Aotearoa New Zealand. The majority of patients receive immunosuppression, however, were left with significant kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.